Breaking News Instant updates and real-time market news.

MYOV

Myovant Sciences

$19.20

0.49 (2.62%)

08:10
02/13/19
02/13
08:10
02/13/19
08:10

Barclays upgrades Myovant to Overweight on bullish women's health survey

Barclays analyst Geoffrey Meacham upgraded Myovant Sciences to Overweight from Equal Weight and raised his price target for the shares to $25 from $22. The analyst says his firm's women's health survey suggests a "robust potential market" for new treatment options for endometriosis and uterine fibroids. Respondents to the survey reported positive experiences with Orilissa and noted increasing patient interest in new therapies, Meacham tells investors in a research note. He believes Myovant will benefit from these market dynamics.

MYOV Myovant Sciences
$19.20

0.49 (2.62%)

07/24/18
SBSH
07/24/18
NO CHANGE
SBSH
Buy
Citi says Myovant may have $102 upside if relugolix priced at parity to elagolix
After AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced that the FDA approved elagolix and Neurocrine said the list price has been set at $28 per day, Citi analyst Robyn Karnauskas noted that she currently models Myovant Sciences' (MYOV) relugolix priced at $10 per day. Modeling relugolix pricing at parity to elagolix and assuming a gross-to-net of 100% would lead to a fair value estimate for Myovant of $146, or the equivalent of $102 of upside from her current price target of $44, Karnauskas stated. The analyst, who models a split market between relugolix and elagolix in endometriosis, keeps a Buy rating on Myovant shares.
09/13/18
JPMS
09/13/18
INITIATION
Target $39
JPMS
Overweight
Myovant Sciences initiated with an Overweight at JPMorgan
JPMorgan analyst Eric Joseph started Myovant Sciences with an Overweight rating and $39 price target. The analyst views Myovant as a "differentiated offering" within the oral gonadotropin-releasing hormone space. Further, he believes the company's advanced prostate cancer program offers pipeline optionality that is not fully reflected in the current valuation.
10/26/18
GSCO
10/26/18
INITIATION
Target $25
GSCO
Neutral
Myovant Sciences initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Dana Flanders started Myovant Sciences with a Neutral rating and $25 price target. The analyst's due diligence suggests a "likely slow build" for the antagonist class. Further, Flanders anticipates "minimal clinical differentiation" between the agents in development. The analyst views Myovant's growth opportunity as attractive but sees competitive markets.
02/13/19
LEHM
02/13/19
UPGRADE
Target $25
LEHM
Overweight
Myovant Sciences upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoffrey Meacham upgraded Myovant Sciences to Overweight and raised his price target for the shares to $25 from $22.

TODAY'S FREE FLY STORIES

CRON

Cronos Group

$22.45

0.22 (0.99%)

, MO

Altria Group

$50.38

-0.14 (-0.28%)

17:37
02/21/19
02/21
17:37
02/21/19
17:37
Hot Stocks
Cronos Group shareholders approve C$2.4B investment from Altria Group »

Cronos Group (CRON)…

CRON

Cronos Group

$22.45

0.22 (0.99%)

MO

Altria Group

$50.38

-0.14 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

BAH

Booz Allen

$53.64

-0.105 (-0.20%)

, GD

General Dynamics

$171.66

-2.78 (-1.59%)

17:36
02/21/19
02/21
17:36
02/21/19
17:36
Hot Stocks
Booz Allen, General Dynamics, Leidos and SAIC awarded DTRA contracts »

Booz Allen (BAH), General…

BAH

Booz Allen

$53.64

-0.105 (-0.20%)

GD

General Dynamics

$171.66

-2.78 (-1.59%)

LDOS

Leidos

$62.87

1.175 (1.90%)

SAIC

SAIC

$75.73

-0.75 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

INFN

Infinera

$4.87

-0.02 (-0.41%)

17:35
02/21/19
02/21
17:35
02/21/19
17:35
Earnings
Infinera reports Q4 EPS (25c), consensus (27c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

ECIFF

EDF

$0.00

(0.00%)

17:33
02/21/19
02/21
17:33
02/21/19
17:33
Downgrade
EDF rating change  »

EDF downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEE

Lee Enterprises

$2.69

0.075 (2.87%)

17:32
02/21/19
02/21
17:32
02/21/19
17:32
Hot Stocks
Lee Enterprises' TownNews acquires CMS business from GTxcel »

Lee Enterprises announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CENX

Century Aluminum

$9.30

0.12 (1.31%)

17:31
02/21/19
02/21
17:31
02/21/19
17:31
Earnings
Century Aluminum reports Q4 EPS (43c), consensus (53c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

EXEL

Exelixis

$21.22

(0.00%)

17:30
02/21/19
02/21
17:30
02/21/19
17:30
Initiation
Exelixis initiated  »

Exelixis initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPSN

Epsilon Energy

$0.00

(0.00%)

17:30
02/21/19
02/21
17:30
02/21/19
17:30
Hot Stocks
Epsilon Energy sees 2019 production growth of 27%-33% y/y »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$14.13

0.245 (1.76%)

17:29
02/21/19
02/21
17:29
02/21/19
17:29
Earnings
SSR Mining sees FY19 gold production 395,000 equivalent ounces »

At the Marigold mine,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ENPH

Enphase Energy

$7.37

0.13 (1.80%)

17:29
02/21/19
02/21
17:29
02/21/19
17:29
Hot Stocks
Park West Asset Management reports 5.4% passive stake in Enphase Energy »

Park West Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EPSN

Epsilon Energy

$0.00

(0.00%)

17:29
02/21/19
02/21
17:29
02/21/19
17:29
Hot Stocks
Epsilon Energy board approves $20M-$25M capital budget for 2019 »

Epsilon Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$14.13

0.245 (1.76%)

17:28
02/21/19
02/21
17:28
02/21/19
17:28
Earnings
SSR Mining reports Q4 adjusted EPS 4c, two estimates 0c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BIIB

Biogen

$320.99

-14.02 (-4.18%)

17:28
02/21/19
02/21
17:28
02/21/19
17:28
Initiation
Biogen initiated  »

Biogen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 28

    May

DBX

Dropbox

$25.58

0.1 (0.39%)

17:27
02/21/19
02/21
17:27
02/21/19
17:27
Earnings
Dropbox sees FY19 revenue $1.63B-$1.64B, consensus $1.6B »

Sees FY19 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

QNST

QuinStreet

$13.52

-0.26 (-1.89%)

17:26
02/21/19
02/21
17:26
02/21/19
17:26
Hot Stocks
Park West Asset Management reports 5.0% passive stake in QuinStreet »

Park West Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 27

    Mar

APPN

Appian

$38.73

0.41 (1.07%)

17:26
02/21/19
02/21
17:26
02/21/19
17:26
Earnings
Appian sees FY19 EPS (46c)-(42c), consensus (44c) »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 07

    Mar

WAB

Wabtec

$73.59

-1.425 (-1.90%)

, GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

17:26
02/21/19
02/21
17:26
02/21/19
17:26
Hot Stocks
S&P announces changes to S&P 400, 500 indices »

Wabtec (WAB) will replace…

WAB

Wabtec

$73.59

-1.425 (-1.90%)

GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

GE

General Electric

$10.03

-0.07 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

DBX

Dropbox

$25.58

0.1 (0.39%)

17:26
02/21/19
02/21
17:26
02/21/19
17:26
Earnings
Dropbox sees Q1 revenue $379M-$382M, consensus $377.03M »

Guidance taken from Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

EIDX

Eidos Therapeutics

$14.99

-0.64 (-4.09%)

17:25
02/21/19
02/21
17:25
02/21/19
17:25
Initiation
Eidos Therapeutics initiated  »

Eidos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

NOC

Northrop Grumman

$287.50

-0.73 (-0.25%)

17:25
02/21/19
02/21
17:25
02/21/19
17:25
Hot Stocks
Northrop Grumman Australia unit to continue work on F-35 program »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

APPN

Appian

$38.73

0.41 (1.07%)

17:25
02/21/19
02/21
17:25
02/21/19
17:25
Earnings
Appian sees Q1 EPS (17c)-(16c), consensus (12c) »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 07

    Mar

APPN

Appian

$38.73

0.41 (1.07%)

17:22
02/21/19
02/21
17:22
02/21/19
17:22
Earnings
Appian reports Q4 EPS (22c), consensus (16c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 07

    Mar

PTGX

Protagonist Therapeutics

$7.32

0.16 (2.23%)

17:20
02/21/19
02/21
17:20
02/21/19
17:20
Initiation
Protagonist Therapeutics initiated  »

Protagonist Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

, WAB

Wabtec

$73.59

-1.425 (-1.90%)

17:20
02/21/19
02/21
17:20
02/21/19
17:20
Hot Stocks
Breaking Hot Stocks news story on Goodyear Tire, Wabtec »

Goodyear Tire to replace…

GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

WAB

Wabtec

$73.59

-1.425 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

WAB

Wabtec

$73.59

-1.425 (-1.90%)

, GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

17:19
02/21/19
02/21
17:19
02/21/19
17:19
Hot Stocks
Wabtec to replace Goodyear Tire in S&P 500 at open on 2/27 »

General Electric (GE) is…

WAB

Wabtec

$73.59

-1.425 (-1.90%)

GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.